Hangzhou, August 28, 2025 – Hangzhou Tigermed Consulting Co., Ltd. (“Tigermed” or the “company”) (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its interim results for the first half of 2025, ended June 30, 2025 (the "Reporting Period").

This press release is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2025 interim results announcement and other relevant announcements published on the websites of the Shenzhen Stock Exchange (www.szse.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk) for further information. 

All financials disclosed in this press release are presented in accordance with China Accounting Standards for Business Enterprises (“CASBE”) except for those specifically noted otherwise.

Continued Recovery in Q2 2025 Results

    Q2 2025 revenue achieved 1,686 million RMB, a quarter-on-quarter increase of 7.8%

    Gross profit reached 508 million RMB, a quarter-on-quarter increase of 8.2%

    Adjusted net profit attributable to owners of the Company reached 108 million RMB, a quarter-on-quarter increase of 6.0%*

* Net profit attributable to shareholders of the Company after deducting extraordinary gain or loss

First Half of 2025 Key Financial Results

    During the reporting period, total revenue achieved 3,250 million RMB

    During the reporting period, gross profit achieved 978 million RMB

    Segment revenue generated from Clinical Trial Solutions reached 1,469 million RMB

    Segment revenue generated from Clinical-related and Lab Services reached RMB 1,781 million

    China revenue reached 1,698 million RMB and Overseas revenue reached 1,553 million RMB

Global Overview

    As of June 30, 2025, our employees reached 10,251 globally, including more than 1,700 overseas employees in 33 countries.

    In 2024, we maintained a leading position in China's clinical outsourcing service market with a market share of 10.6%

    As of June 30, 2025, our clinical team in the U.S. had nearly 200 people, covering 68 cities in 27 states

    After the acquisition of Micron, our clinical operation team in Japan expanded to 200 people, with comprehensive clinical service capabilities covering clinical operations, regulatory affairs, medical imaging, data management, EDC and pharmacovigilance, etc.

    As of June 30, 2025, our clinical operation team in South Korea expanded to over 450 people, having completed over 2,600 clinical trials and related service projects.

    As of June 30, 2025, over 70 Phase I clinical trials have been conducted in Australia, with over 40 experienced local PMs and CRAs deployed in Australia.

    As of June 30, 2025, our clinical operation team in Southeast Asia expanded to over 70 people, who had handled over 100 Phase I-IV clinical trials.

    In collaboration with local African institutions and organizations such as Purpose Africa and Africare, we made efforts to empower Chinese pharmaceutical products in “going global” practice and to expand clinical research operations in Africa.

    As of June 30, 2025, we cumulatively handled 150 multi-region clinical trials (MRCTs).

Business Highlight: Clinical Trial Solutions (“CTS”)

    As of June 30, 2025, we had a total number of 646 ongoing clinical trial projects, including 409 China-only projects, 194 overseas single-region projects and 43 multi-region clinical trial projects.

    As of June 30, 2025, our Regulatory Affairs (RA) team cumulatively finished 1,351 registration and submission projects.

    In H1 2025, Our Medical Device & IVD team supported the successful launch of 3 innovative MD products (i.e. Cryoablation Device, Transcatheter Tricuspid Valve Annuloplasty System, and Gastrointestinal Endoscopic Surgical Robot) into the market, and supported the FDA approval and the market launch of Felix™ NeuroAI™ Wristband --- the world's first AI plus Essential Tremor Treatment Device.

    As of June 30, 2025, our global PV client base exceeded 300 clients, and our PV team had cumulatively handled 2,000+ PV projects, and had participated in 39 Class 1 new drug approvals in China.

    Medical translation business added 30 new customers In H1 2025, including 17 pharmaceutical companies and 13 medical device companies; Finished translation of approximately 200 million words in H1 2025.

    As of June 30, 2025, Tigermed E-Site had deployed 19 regions in China, with 300 key strategic sites and 98 green channel sites

Business Highlight: Clinical-related and Lab Services (“CRLS”)

    As of June 30, 2025, we had a total of 4,549 ongoing lab service projects.

    In H1 2025, both our Bioanalytical Laboratory in Suzhou and Macromolecule Bioanalytical Laboratory in Shanghai had successfully passed on-site inspections by the U.S. FDA with "No Findings".

    In May 2025, our CDMO R&D and Manufacture Base located in Exton, Pennsylvania, US, officially commenced operations, further expanding our business footprint in the field of laboratory services.

    As of June 30, 2025, we had a total of 893 ongoing Data Management and Statistical Analysis projects.

    As of June 30, 2025, the total number of our ongoing SMO projects was 2,443. The number of our newly-signed SMO orders in H1 2025 grew by 12% YoY compared to H1 2024.

Acquisition of Japanese CRO Micron

Founded in 2005 and headquartered in Tokyo, Micron is a Japan-based Contract Research Organization (CRO) focusing in medical imaging and clinical trial services with over 160 employees. Micron brings nearly two decades of expertise in clinical research and the largest team of imaging experts in Asia, served more than 250 clients and contributed to the successful approval of over 40 drugs. Following the acquisition, Micron will be integrated into Tigermed’s global network as a key entity under Tigermed Japan. Leveraging mature service team and deep regional expertise from Micron, as well as its worldwide operational layout, Tigermed will enhance its coverage across Japan and Asia-Pacific in medical imaging capabilities.

MSCI ESG AAA Rating

The company was awarded an MSCI Environmental, Social, and Governance (ESG) Rating of AAA in 2025, the highest rating in the industry. This recognition underscores our commitment to excellence in ESG practices, positioning us as a leader in sustainable business performance. MSCI’s AAA rating is reserved for companies that demonstrate superior ESG performance and strong resilience to long-term risks. Since receiving its first MSCI ESG rating in 2020, Tigermed has consistently improved its performance, moving from a baseline rating to AA in 2023 and now achieving AAA.

Forward-Looking Statements

The information communicated herein may contain certain “forward-looking statements”, which are not historical facts but instead include predictions about future events based on our beliefs and information currently made available to us. Although we believe that these predictions are reasonable on the date hereof, future events are inherently uncertain and these forward-looking statements may turn out to be incorrect. Forward-looking statements involve risk and uncertainty by nature because they relate to events and will depend on circumstances that will occur in the future relating to, inter alia, our ability to compete effectively, our ability to develop and market new service offerings, our ability to expand into new markets, the risks associated with listed subsidiaries of the Company, unforeseeable international tensions, regulatory or governmental scrutiny in certain countries, the impact of emergencies and other force majeure events. We undertake no obligations to update forward-looking statements or to adapt them to future events or developments except as required by applicable laws or listing rules. Any investment in any securities issued by the Company or its subsidiaries will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, you should not rely on these forward-looking statements.

About Tigermed

Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,600 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients’ needs, and ultimately saving lives.

For more information:

Investor: ir@tigermedgrp.com

Media: pr@tigermedgrp.com